Lombard summary December 2005



Bridgehead International provides Experts’ Report for AIM listing of Lombard Medical Technologies PLC

Lombard Medical Technologies PLC, a developer of stent grafts and other medical products, announced on 7th December 2005 that it had successfully completed an initial public offering on the AIM market of the London Stock Exchange, raising £26.2 million of new money (before expenses) for the Company, via a placing with institutional investors conducted by Code Securities Limited (now Nomura Code Securities Ltd).

Bridgehead International carried out independent due diligence on behalf of Lombard and Code Securities, in the form of what is known as the 'Experts' Report', which was published in the Listing Document.

The publication of a report such as this satisfies regulatory requirements in certain cases, but it is the process leading up to its preparation that adds real value. Bridgehead’s expert consultants review many aspects of the Company's technical and commercial operations and, during the process, the Company and its Advisors gain an insight into concerns that potential investors are likely to have. The Company then has the opportunity, in advance of publication of the prospectus, either to take action to avoid these potential concerns or to have available the information or plans to address them.

Bridgehead is widely recognised as the leading provider of independent reports to support fundraising in the pharmaceutical and medical device fields in the UK, it has also worked with companies raising finance in the USA, Scandinavia and the Far East. Some of the companies that Bridgehead has reviewed as part of stock market listings and other investment rounds are: Vectura Group plc, Inion Ltd, ProStrakan Group plc, Alizyme plc Cardiomag Imaging Inc, GeneMedix plc, GW Pharmaceuticals plc, Akers Bioscience Inc and CustomVis plc.

Top